Poway, CA (PRWEB) August 25, 2016 -- VetStem Biopharma, Inc., announced that a major United States patent has been issued directly to VetStem. This patent covers methods for extracting/preparing and using adipose tissue-derived stem cells for preventing or treating inflammation at site of musculoskeletal injury in any mammal, including humans. This patent will provide coverage for the on-going commercial and development programs at VetStem and may be available for licensing to other companies interested in working in this field. VetStem already received issuance of a similar patent for the EU in 2014 and has similar patent applications pending in other countries.
This new patent issued to VetStem adds to the other patents in the VetStem portfolio that cover methods of using regenerative cells from adipose tissue for the eye, pancreas, liver, bone and muscle. VetStem has exclusive worldwide rights for veterinary use of these other licensed patents (over 55 issued and 70 pending patents) and this strengthens further the company’s intellectual property position in this rapidly developing field.
As the first company in the world to offer fat derived stem cell services for veterinary use, VetStem has rapidly developed the market, providing treatments to over 12,000 horses, dogs, cats and exotic species. “Intellectual property rights are critical and can be confusing in a rapidly developing market with evolving technology.” said Bob Harman, DVM, MPVM, CEO of VetStem. “We have taken appropriate actions to protect the market that we are creating in regenerative veterinary medicine and to ensure that the value of the company is optimized. The value of this technology has increased greatly since the founding of the company in 2002 as the business model, therapeutic activity of the cells, and ease of tissue collection have all been demonstrated.”
About VetStem Biopharma
VetStem Biopharma is a veterinarian-lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 14 years and 12,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.
Alexis Nahama, VetStem Biopharma, http://www.vet-stem.com/, +1 858-748-2004 Ext: 103, [email protected]
SOURCE VetStem Biopharma